LeafNLP Demos
Back to explore

Report #2867239

Received Oct 20, 2025

Reports are unverified and do not show that a vaccine caused an event. Full disclaimer

Overview

Sex
Female
Age
Age unknown
State
PA
Recovered
Unknown
Vaccinated
Jul 19, 2025
Onset
Jul 19, 2025
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
HEPHEP B (HEPLISAV-B)DYNAVAX TECHNOLOGIES CORPORATION1946064IM

Symptoms (2)

Interchange of vaccine productsNo adverse event

Symptom narrative

Had a Dose of Recombivax then a Dose of HEPLISAV-B; Initial report received on 15-Sep-2025. A pharmacist reported that a 40-year-old female received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization after receiving RECOMBIVAX previously. Medical history included a sulfa allergy. No concomitant medications were reported. On 19-Jun-2025, the patient received dose 1 of a hepatitis B vaccine [RECOMBIVAX HB (lot number not available)]. On 19-Jul-2025, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number 946064, expiration date 31-Aug-2027, and NDC number 43528-003-05; site not available)] intramuscularly. No other side effects were reported. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.

Current illness

Drug allergy (Unknown reaction)

Other medications

Recombivax